- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy
© Parlato et al; licensee BioMed Central Ltd. 2010
Received: 29 July 2009
Accepted: 12 June 2010
Published: 12 June 2010
The purpose of this work was to explore the knowledge and acceptance of Varicella Zoster Virus (VZV)-Herpes Zoster (HZ) vaccination in the general Italian population, where the HZ vaccine has not yet been distributed, using a prevalence study of subjects from two regions in Italy.
A group of 3,173 individuals were interviewed using a questionnaire. The youngest age group (≤ 20 year) was composed of students interviewed at university. The middle age group (21-40 years) and the older age group (≥ 41 years) were interviewed by general practitioners in their office.
In both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects reported receiving the VZV vaccination. Regarding HZ, 2,749 (86.6%) individuals stated that they knew of the virus and 2,233 (70%) were willing to be vaccinated against HZ. The majority of people willing to be vaccinated were in the middle and older age groups (36.6% and 44.7%, respectively).
Compliance versus vaccination results were satisfactory and probably, with the upcoming availability of the HZ vaccine in Italy, adults will be favourably disposed towards vaccination.
Worldwide, varicella-zoster virus (VZV) infection (chickenpox) affects millions of individuals, causing significant suffering. During primary infection, the virus migrates to the dorsal root and cranial root ganglia, where it remains latent. Herpes zoster (HZ, shingles) is the result of reactivation of dormant VZV in the ganglia . HZ causes acute and chronic morbidity and is characterized by a painful vesicular unilateral dermatomal rash. The most common HZ complication is post-herpetic neuralgia (PHN), which consists of burning pain, paresthesias, dysesthesia, pruritus, or anesthesia in the affected area and most frequently develops in subjects over 60 years of age. The risk of developing HZ in people exposed to VZV ranges from 10% to 30%, with an increased incidence in older individuals and in immunocompromised hosts [2–6]. Cell-mediate immunity (CMI) is thought to be important in defense against VZV infection. Therefore, a defective CMI is a major factor in virus reactivation .
It has been predicted that a quarter of the general population will be affected by HZV reactivation during their lifetime . In the United States (US), an estimated one million cases of HZ infection occur each year, with an incidence of 11.12 cases per 1,000 patient-years and there are higher incidence rates and number of hospitalizations among older adults (> 50 years) [8–12]. Studies examining the general population of European countries demonstrated that the incidence of HZ in all ages ranges was from 1.2 to 4.8 cases per 1000 person-years and, among people > 60 years of age, it was 7.2 to 11.8 cases per 1,000 person-years [13, 14]. Also, in a Spanish study, the majority of hospitalizations for HZ occurred in adults over 50 years of age . In Italy, a regional survey conducted in 2007 reported a total incidence of 1.74 HZ cases/1000 population per year, over a period of 14 years and an incidence of hospital admissions of 0.12/1000 inhabitants, with an average cost of €4082.59 per hospitalization .
In 2006, an HZ vaccine was approved by the US Food and Drug Administration (US FDA) and recommended by the Advisory Committee on Immunization Practices (ACIP) for the prevention of shingles in individuals ≥ 60 years old. In the same year, European Medicines Agency (EMEA) gave its Marketing Authorization valid throughout the European Union to this product. EU approval states that the recommended age of vaccination starts from 50 yrs of age instead of 60 yrs of age as in the USA http://www.ema.europa.eu/humandocs/Humans/EPAR/zostavax/zostavax.htm. This new vaccine is made of the same live attenuated VZV strain used in the varicella vaccine, but it has a potency at least 14-times higher than that of single-antigen varicella vaccine, which is necessary to confer protection against zoster . It boosts the CMI against HZ, thus reducing the incidence of the disease and severity [8, 18–20]. Efficacy, safety and tolerability of a high titre VZV vaccine for the prevention of HZ infection and its sequelae were demonstrated in a multicentric study of over 38,000 older adults [9, 10].
Nowadays, the vaccine is only distributed in USA; vaccination has been recommended in Austria and Switzerland and it should be soon included in European geriatric guidelines .
In Italy, the HZ vaccine is not yet commercially available, though, it is about to be distributed. However, few population-based studies have been performed in Italy assessing the subjective perception of the relevance of VZV to health and the importance of vaccination. The aim of this study was to explore the knowledge of VZV infections in the general population of two Italian regions and analyze the VZV vaccine immunization status and the acceptance of HZ vaccination.
The sample group was composed by 3,173 subjects from two Italian Regions, Campania and Lazio. Subjects were consecutively enrolled: the youngest age group (≤ 20 year) was composed of university students interviewed by teachers; the middle age group (21-40 years) and the eldest age group (≥ 41 years) were interviewed by general practitioners in their office. Face-to-face interviews were done by administrating a brief questionnaire divided in two sections (Additional file 1).
The first section included general questions about sex, age, level of education, residence and nationality. In the second section, the subjects were asked about their knowledge of and personal experience with both chickenpox and shingles, and also, about their compliance versus HZ vaccination. Questionnaire was developed on the basis of previous experiences in collaboration with Sanofi Pasteur MSD and tested on a sample of university students. Statistical analysis was performed using the Epi Info software, version 3.32.
Characteristics of subjects interviewed
Area of residence:
Individuals who know or who were affected by VZV-associated diseases and their compliance with vaccinations
knowing (n. 3071)
affected (n. 2256)
immunized (n. 165)
knowing (n. 2749)
affected (n. 352)
compliance (n. 2233)
young N = 594
adults N = 1,162
older N = 1,417
Among the 3,173 individuals interviewed about their knowledge of HZ, with respect to the acceptance of the vaccination, 1,960 (61.77%) individuals claimed to be amenable towards this type of prevention because they were familiar with the disease (OR 1.4, CI.95 = 1.17-1.82, p-value = 7 × 10-4). Furthermore, there were more people who were willing to be vaccinated in the middle and older adult age groups (36.6% and 44.7%, respectively) than in the youngest age class (OR 1.34, CI.95 = 1.07-1.66, p-value = 7 × 10-3).
VZV can cause two clinical conditions, the first results from the primary infection and the second is due to reactivation of the virus following the initial infection. Both of these diseases are often associated with severe complications. In 1995, a varicella vaccination program was implemented in the United States . The immediate goal of the extensive vaccination against VZV was to significantly decrease the morbidity and mortality associated with the disease. With widespread vaccination, there has been a concomitant decline in the incidence of the disease, along with a decrease in hospitalizations and deaths due to VZV infection . To improve protection, a two-dose schedule of immunization was recommended for routine use in children by the Centers for Disease Control and Prevention (CDCs) in June 2006. At the same time, the licensure of the combined measles-mumps-rubella-varicella vaccine was completed, which allowed harmonization of immunization against these four viruses with one injection given twice in childhood [23, 24].
The Shingles Prevention Study, a case-control study examining the widespread immunization against VZV, established that the zoster vaccine was safe, well-tolerated, and effective at reducing the burden of illness due to HZ and the incidence of PHN [9, 10, 25–27].
In 2006, the US FDA licensed the HZ vaccine , which promises to reduce the morbidity and mortality of HZ. In fact, administration of the vaccine to younger people may offer a good cost-benefit balance .
The availability of a specific anti-zoster vaccine could offer an important tool for reducing health problems and improve the overall quality of life in the elderly, as demonstrated by several studies [29–32]. A combined immunization against both varicella in childhood and HZ in adulthood in the developed world could improve the control of the virus . The future challenge is represented by the prediction of how the decrease in VZV circulation will affect immunity among both vaccinated and unvaccinated individuals: varicella will continue to occur even in a highly immunized population, because of the ability of VZV to reactivate as zoster. Studies have predicted that there will be an increase in HZ incidence until the adult population becomes predominantly composed of individuals with vaccine-induced immunity who do not harbour wild-type VZV . Moreover, VZV vaccination in children, without optimal coverage, can shift the disease to adults, leading to severe illness and a higher incidence of herpes zoster. Vaccination strategies will likely need to be adjusted as the epidemiology of VZV and risk factors continues to evolve . Some risk factors may help to redirect preventive vaccination strategies. Hicks et al. demonstrated that, in a cohort of non-immunocompromised subjects, there was a strong association between the development of HZ and a family history of HZ, suggesting that these individuals were at high risk for HZ infection. These individuals could be the primary target for vaccination, thus, decreasing both their possibility of VZV infection and health care expenditures due to HZ morbidity .
Age can also be considered as a risk factor: active HZV vaccination of individuals > 50 years of age, simultaneously or in sequence with anti-influenza vaccination, has been demonstrated to be an effective, well-tolerated strategy [35, 36]. Few studies have been conducted to investigate the social and epidemiological problems related to shingles disease or to the spread of immunization. In a recent global survey about awareness, knowledge, symptoms and treatment of HZ among 8,688 adults ≥ 50 years of age in 22 countries, there was wide variation in HZ awareness among the different areas and, almost, universally poor knowledge of the causes and symptoms of HZ were reported. Moreover, the majority of respondents were unaware of their risk of HZ. This survey suggests a population-wide effort to improve global awareness of HZ would be required for a successful vaccine initiative .
In the Netherlands, Opstelten et al. evaluated the determinants of non-compliance with HZ vaccination in community-dwelling elderly to whom a free HZ vaccination was offered simultaneously with the yearly influenza vaccination. In all, 690 patients (39%) were vaccinated against HZ, while 1,349 patients (76%) accepted influenza vaccination. Determinants of non-compliance with HZ vaccination included the perceived lack of recommendation by the GP, unwillingness to comply with the doctor's advice, perception of low risk for contracting HZ, perception of a short pain duration for HZ and the opinion that vaccinations weaken natural immunity .
In the present study we have compared attitude, knowledge and experience about VZV-associated diseases of individuals from different age groups in two different regions in Italy. In both regions, the majority of subjects had been affected by varicella infection, while a low percentage (5%) had been vaccinated against VZV. Regarding perception and availability of the HZ vaccination, in both regions, adults over the age of 21 seemed to be willing to accept this vaccination. This is probably due to greater knowledge of the infection/disease in this population and to a direct, or indirect, experience with HZ in the older age group.
Finally, limits and biases of this study should be mentioned. A cross-sectional study measures the prevalence of an outcome of interest in a certain population at a certain time point or over a short period. We have explored the acceptability of the HZ vaccination in people using face to face interviews, carried out by their pratictioners and in university staff. We randomly selected the interviewed population in two Italian regions, Lazio and Campania. Indeed, each of the associations identified in the current study must be interpreted with caution because our sample is not representative of the entire Italian population and study inclusion or exclusion could have been mediated by the interviewer during the face to face interview. A cross-sectional design may also make it difficult to establish the cause and the effect, i.e., for this study, the vaccine acceptability versus the knowledge of the disease and the vaccine acceptability versus the age group.
Moreover, it has to be remarked that our investigation didn't concern economical aspects of vaccination strategies. Therefore, the questionnaire do not comprise questions about willingness-to-pay of interviewed subjects.
In this study compliance versus vaccination results were satisfactory and it is possible to assume that, with the upcoming availability of a HZ vaccine in Italy, adults will be the population favourably disposed towards in vaccination. However, the reported compliance must be considered only as an estimate and should be verified by larger public health interventions and broaden cost-effectiveness analyses.
The authors thank Sanofi Pasteur MSD S.p.A. for its cooperation.
- Weinberg JM: Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol. 2007, 57: S130-S135. 10.1016/j.jaad.2007.08.046.View ArticlePubMedGoogle Scholar
- Hope-Simpson RE: The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med. 1965, 58: 9-20.PubMedPubMed CentralGoogle Scholar
- Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry OH: Population-based study of herpes zoster and its sequelae. Medicine. 1982, 61 (5): 310-316. 10.1097/00005792-198209000-00003.View ArticlePubMedGoogle Scholar
- Brisson M, Edmunds WJ, Law B, et al: Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001, 127: 305-314. 10.1017/S0950268801005921.View ArticlePubMedPubMed CentralGoogle Scholar
- Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis. 2004, 4: 26-33. 10.1016/S1473-3099(03)00857-0.View ArticlePubMedGoogle Scholar
- Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster. The European view. Am J Clin Dermatol. 2995, 6 (5): 317-325. 10.2165/00128071-200506050-00005.View ArticleGoogle Scholar
- Brisson M, Edmunds WJ: Epidemiology of Varicella-Zoster virus in England and Wales. J Med Virol. 2003, 14: 70-89.Google Scholar
- Weaver BA: The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States. JAOA. 2007, 107 (1): 2-7.Google Scholar
- Oxman MN, Levin MJ, Johnson GR, Shingles Prevention Study Group, et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352: 2271-84. 10.1056/NEJMoa051016.View ArticlePubMedGoogle Scholar
- Simberkoff MS, Arbeit RD, Johnson GR, et al: Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010, 152 (9): 545-54.View ArticlePubMedGoogle Scholar
- Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA: The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005, 20: 748-753. 10.1111/j.1525-1497.2005.0150.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Coplan P, Black S, Rojas C, et al: Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. Pediatr Infect Dis J. 2001, 20: 641-645. 10.1097/00006454-200107000-00002.View ArticlePubMedGoogle Scholar
- Dworkin RH, Schmader KE: Epidemiology and natural history of herpes zoster and postherpetic neuralgia. Herpes zoster and postherpetic neuralgia. Edited by: Watson CPN, Gerhon AA. 2001, New York: Elsevier Press, 39-64.Google Scholar
- Schmader K, Gnann JW, Watson CP: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008, 197 (1): 207-15. 10.1086/522152.View ArticleGoogle Scholar
- Gil A Sanmartin M, Carrasco P, Gonzales A: Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004, 22: 3947-51. 10.1016/j.vaccine.2004.04.004.View ArticleGoogle Scholar
- Di Legami V, Gianino MM, Atti MC, Massari M, Migliardi A, Tomba GS, Zotti C, Zoster Study Group: Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007, 25 (43): 7598-604. 10.1016/j.vaccine.2007.07.049.View ArticlePubMedGoogle Scholar
- Creed R, Satyaprakash A, Ravanfar P: Varicella zoster vaccines. Dermatol Ther. 2009, 22 (2): 143-9. 10.1111/j.1529-8019.2009.01226.x.View ArticlePubMedGoogle Scholar
- Mitka M: FDA approve Schingles Vaccine - Herpes Zoster Vaccine targets older adults. Medical News and Perspectives. 2006, 296: 157-Google Scholar
- Pellissier JM, Brisson M, Levin MJ: Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007, 25 (49): 8326-37. 10.1016/j.vaccine.2007.09.066.View ArticlePubMedGoogle Scholar
- Harpaz R, Ortega-Sanchez IR, Steward JF: Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008, 57: 1-30.PubMedGoogle Scholar
- Marino MG, Bagnato B, Torella I, Franco E: Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications. Ig Sanita Pubbl. 2009, 65 (3): 299-311.PubMedGoogle Scholar
- Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF: The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis. 2008, 197 (1): 224-7. 10.1086/522162.View ArticleGoogle Scholar
- Gershon AA, Katz SL: Perspective on live varicella vaccine. J Infect Dis. 2008, 197 (2): 242-5. 10.1086/522151.View ArticleGoogle Scholar
- Hambleton S: Prevention of varicella and zoster by live attenuated VZV vaccine. Front Biosc. 2008, 13: 2696-704. 10.2741/2876.View ArticleGoogle Scholar
- Betts RF: Vaccination strategies for the prevention of Herpes zoster and postherpetic neuralgia. J Am Acad Dermatol. 2007, 57 (6): 143-7. 10.1016/j.jaad.2007.09.017.View ArticleGoogle Scholar
- Levin MJ, Shmader K: Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. Herpes. 2007, 14 (2): 45-7.PubMedGoogle Scholar
- Gnann JW: Vaccination to prevent herpes zoster in older adults. J Pain. 2008, 9 (1): 31-6. 10.1016/j.jpain.2007.10.007.View ArticleGoogle Scholar
- Gelb LD: Preventing herpes zoster through vaccination. Ophtalmology. 2008, 115 (2): 35-8. 10.1016/j.ophtha.2007.10.015.View ArticleGoogle Scholar
- Franco E, Zaratti L, Ambrosini Spinella S: It is possible to prevent herpes zoster through vaccination?. Ig San Pubbl. 2007, 63 (2): 191-5.Google Scholar
- Lieu TA, Ortega-Sanchez I, Ray GT, et al: Community and patient values for preventing herpes zoster. Pharmacoeconomics. 2008, 26 (3): 235-49. 10.2165/00019053-200826030-00006.View ArticlePubMedGoogle Scholar
- Adams EN, Parnapy S, Bautista P: Herpes zoster and vaccination: a clinical review. Am J Health Syst Pharm. 2010, 67 (9): 724-7. 10.2146/ajhp090118.View ArticlePubMedGoogle Scholar
- Moore L, Remy V, Martin M, Beillat M, McGuire A: A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010, 8 (1): 7-10.1186/1478-7547-8-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Hambleton S, Gershon AA: The impact of varicella vaccination in the United States. Semin Pediatr Infect Dis. 2005, 16: 38-43. 10.1053/j.spid.2004.09.010.View ArticlePubMedGoogle Scholar
- Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring S: Family history as risk factor for herpes zoster. Arch Dermatol. 2008, 144 (5): 603-8. 10.1001/archderm.144.5.603.View ArticlePubMedGoogle Scholar
- Kerzner B, Murray AV, Cheng F, et al: Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007, 55 (10): 1499-507. 10.1111/j.1532-5415.2007.01397.x.View ArticlePubMedGoogle Scholar
- Cunningham AL, Breuer J, Dwyer DE, et al: The prevention and management of herpes zoster. Med J Aust. 2008, 188 (3): 171-6.PubMedGoogle Scholar
- Paek E, Johnson R: Public Awareness and Knowledge of Herpes Zoster: Results of a Global Survey. Gerontology. 2010, 56 (1): 20-31. 10.1159/000240046.View ArticlePubMedGoogle Scholar
- Opstelten W, van Essen GA, Hak E: Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine. 2009, 27 (2): 192-6.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/10/333/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.